Loading organizations...
§ Private Profile · 245 1st St, Fl 12, Cambridge, MA 02142-1292
Healthcare marketing agency for pharmaceutical and biotechnology companies, specializing in rare and orphan diseases.
Key people at cambridge biomarketing Group.
Cambridge BioMarketing Group is a Cambridge, Massachusetts-based healthcare marketing and communications agency that specializes in developing campaigns for pharmaceutical and biotechnology companies focused on rare, orphan, and ultra-orphan conditions. The agency operates globally and was acquired in 2017 for a total valuation of $35 million, which included a $30 million upfront payment and up to $5 million in contingent consideration. Following its initial acquisition by UDG Healthcare, the firm later became a division of Everyday Health and was subsequently integrated into the Ashfield Health network to form the Mind+Matter agency. Operating under the leadership of Chief Executive Officer Maureen Franco, the organization is now part of a broader corporate network that employs over 1,450 professionals across its global offices, including a secondary location in Oakland, California. Cambridge BioMarketing Group was originally founded in 2001.
Key people at cambridge biomarketing Group.
Cambridge BioMarketing Group is a full-service, global healthcare marketing and communications agency specializing in the pharmaceutical and biotechnology sectors.[1][4] The company focuses on creating marketing and brand strategies, particularly for underserved rare disease populations, guided by the principles of "patients first, people first," with a mission to generate awareness, hope, and connections to life-changing treatments for patient communities.[2]
It serves pharmaceutical and biotech clients by developing unique, powerful campaigns that highlight patient stories and foster community, operating from locations including Boston, MA, and the UK, with reported revenue of $435.3 million and around 163 employees.[2][3]
Cambridge BioMarketing Group emerged as a specialized agency in healthcare marketing, with a strong emphasis on rare diseases and patient-centric strategies, though specific founding year and founders are not detailed in available records.[1][2] The company's evolution centers on its rebranding, featuring a signature fingerprint logo that symbolizes its dynamic mission and serves as a daily reminder of impacting lives, as integrated into its Boston workspace design.[2]
Pivotal moments include its expansion into global operations and a focus on collaborative environments, such as the Sasaki-designed office that prioritizes community, shared purpose, and minimal hierarchy to support creative work for patient communities.[2]
Cambridge BioMarketing rides the trend of personalized medicine and rare disease therapeutics in biotech, where marketing plays a key role in patient engagement amid growing demand for targeted therapies.[2] Timing aligns with expanding pharma-biotech pipelines for orphan drugs, amplified by digital campaigns that bridge patients to treatments in underserved areas.[1][4]
Market forces like rising rare disease awareness and regulatory support for patient-focused communications favor its model, influencing the ecosystem by humanizing biotech innovations and accelerating adoption through storytelling and community strategies.[2]
Cambridge BioMarketing is poised to expand its global footprint in rare disease marketing as biotech funding surges and AI-driven personalization enhances patient outreach. Trends like immersive digital campaigns and data-informed strategies will shape its growth, potentially amplifying its influence in connecting therapies to patients. This patient-first approach positions it to lead in an ecosystem increasingly valuing human impact over volume.
